Almarzooqi Ali, Zidan Marwan
Neurology, Rashid Hospital, Dubai, ARE.
Statistics, Rashid Hospital, Dubai, ARE.
Cureus. 2024 Aug 18;16(8):e67113. doi: 10.7759/cureus.67113. eCollection 2024 Aug.
Migraine is a prevalent neurological disorder causing recurrent headaches that significantly impact daily life. Erenumab, a calcitonin gene-related peptide (CGRP) receptor antagonist, has emerged as a promising treatment for migraine. CGRP is thought to play a role in migraine pathophysiology, and erenumab works by blocking CGRP binding to its receptors. Erenumab has been found to be effective in reducing migraine frequency, with potential benefits for improving patient outcomes. This study investigated the impact of erenumab on migraine disability in patients treated at Dubai Health facilities. We specifically assessed changes in Migraine Disability Assessment Scale (MIDAS) scores before and after a three-month treatment period.
This retrospective analysis examined data from 26 patients diagnosed with migraine according to the established criteria. All patients received erenumab treatment for three months. MIDAS, a validated tool, was used to quantify migraine-related disability at baseline and after treatment completion. Due to potential skewness in the data distribution, the statistical analysis focused on the median change in MIDAS scores across groups based on gender and erenumab dosage. Non-parametric tests were employed to assess group differences.
Erenumab treatment resulted in a median decrease of 13 points in MIDAS scores, suggesting a potential improvement in migraine disability at three months. Statistical analysis revealed no statistically significant group differences regarding MIDAS score changes between genders or erenumab dosage groups. However, trends toward improvement were observed in all subgroups.
While not statistically significant due to the limited sample size and the absence of a control group, these findings suggest a potential benefit of erenumab in reducing migraine disability. Future research with more extensive, controlled trials is warranted to definitively assess erenumab's effectiveness and explore potential treatment regimen variations for optimal patient outcomes.
偏头痛是一种常见的神经系统疾病，会导致反复头痛，对日常生活产生重大影响。erenumab是一种降钙素基因相关肽（CGRP）受体拮抗剂，已成为一种有前景的偏头痛治疗药物。CGRP被认为在偏头痛的病理生理学中起作用，而erenumab通过阻断CGRP与其受体的结合发挥作用。已发现erenumab在降低偏头痛发作频率方面有效，对改善患者预后具有潜在益处。本研究调查了erenumab对在迪拜医疗机构接受治疗的偏头痛患者残疾情况的影响。我们特别评估了三个月治疗期前后偏头痛残疾评估量表（MIDAS）评分的变化。
这项回顾性分析检查了26例根据既定标准诊断为偏头痛的患者的数据。所有患者均接受了三个月的erenumab治疗。使用经过验证的工具MIDAS在基线和治疗完成后对偏头痛相关残疾进行量化。由于数据分布可能存在偏态，统计分析重点关注基于性别和erenumab剂量的各组MIDAS评分中位数变化。采用非参数检验评估组间差异。
erenumab治疗使MIDAS评分中位数下降了13分，表明三个月时偏头痛残疾情况可能有所改善。统计分析显示，在MIDAS评分变化方面，性别或erenumab剂量组之间没有统计学上的显著组间差异。然而，在所有亚组中均观察到改善趋势。
尽管由于样本量有限且缺乏对照组，结果无统计学意义，但这些发现表明erenumab在降低偏头痛残疾方面可能有益。有必要进行更广泛的对照试验的未来研究，以明确评估erenumab的有效性，并探索潜在的治疗方案变化以实现最佳患者预后。
